IL17A and systemic lupus erythematosus: Conversely, in SLE mice models, inhibition of IL-17A using antibodies results in decreased blood pressure and mitigated vascular remodeling, indicating a lasting impact on vascular architecture beyond mere hemodynamic changes (82).